Cargando…

Dental pulp stem cells can improve muscle dysfunction in animal models of Duchenne muscular dystrophy

BACKGROUND: Duchenne muscular dystrophy (DMD) is an inherited progressive disorder that causes skeletal and cardiac muscle deterioration with chronic inflammation. Dental pulp stem cells (DPSCs) are attractive candidates for cell-based strategies for DMD because of their immunosuppressive properties...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nitahara-Kasahara, Yuko, Kuraoka, Mutsuki, Guillermo, Posadas Herrera, Hayashita-Kinoh, Hiromi, Maruoka, Yasunobu, Nakamura-Takahasi, Aki, Kimura, Koichi, Takeda, Shin’ichi, Okada, Takashi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831244/ https://www.ncbi.nlm.nih.gov/pubmed/33494794 http://dx.doi.org/10.1186/s13287-020-02099-3

Ejemplares similares

Enhanced cell survival and therapeutic benefits of IL-10-expressing multipotent mesenchymal stromal cells for muscular dystrophy
por: Nitahara-Kasahara, Yuko, et al.
Publicado: (2021)

Improved transduction of canine X-linked muscular dystrophy with rAAV9-microdystrophin via multipotent MSC pretreatment
por: Hayashita-Kinoh, Hiromi, et al.
Publicado: (2020)

Inflammatory predisposition predicts disease phenotypes in muscular dystrophy
por: Nitahara-Kasahara, Yuko, et al.
Publicado: (2016)

Initial Pulmonary Respiration Causes Massive Diaphragm Damage and Hyper-CKemia in Duchenne Muscular Dystrophy Dog
por: Nakamura, Akinori, et al.
Publicado: (2013)

Robust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9
por: Okada, Hironori, et al.
Publicado: (2013)

Development of outcome measures according to dystrophic phenotypes in canine X-linked muscular dystrophy in Japan
por: Kuraoka, Mutsuki, et al.
Publicado: (2021)

Exon-Skipping in Duchenne Muscular Dystrophy
por: Takeda, Shin’ichi, et al.
Publicado: (2021)

Current Challenges and Future Directions in Recombinant AAV-Mediated Gene Therapy of Duchenne Muscular Dystrophy
por: Okada, Takashi, et al.
Publicado: (2013)

Immunomodulatory amnion-derived mesenchymal stromal cells preserve muscle function in a mouse model of Duchenne muscular dystrophy
por: Nitahara-Kasahara, Yuko, et al.
Publicado: (2023)

Mammalian Models of Duchenne Muscular Dystrophy: Pathological Characteristics and Therapeutic Applications
por: Nakamura, Akinori, et al.
Publicado: (2011)

Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors
por: Miyatake, Shouta, et al.
Publicado: (2016)

Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches
por: Shimizu-Motohashi, Yuko, et al.
Publicado: (2019)

A phase I study of TAS‐205 in patients with Duchenne muscular dystrophy
por: Takeshita, Eri, et al.
Publicado: (2018)

Trends in steroid therapy for Duchenne muscular dystrophy in Japan
por: Takeuchi, Fumi, et al.
Publicado: (2016)

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
por: Miskew Nichols, Bailey, et al.
Publicado: (2016)

Comparison of Experimental Protocols of Physical Exercise for mdx Mice and Duchenne Muscular Dystrophy Patients
por: Hyzewicz, Janek, et al.
Publicado: (2015)

Accelerometric outcomes of motor function related to clinical evaluations and muscle involvement in dystrophic dogs
por: Kuraoka, Mutsuki, et al.
Publicado: (2018)

Characterization of a novel microRNA, miR-188, elevated in serum of muscular dystrophy dog model
por: Shibasaki, Hiroyuki, et al.
Publicado: (2019)

Prednisolone improves walking in Japanese Duchenne muscular dystrophy patients
por: Takeuchi, Fumi, et al.
Publicado: (2013)

rAAV8 and rAAV9-Mediated Long-Term Muscle Transduction with Tacrolimus (FK506) in Non-Human Primates
por: Ishii, Akiko, et al.
Publicado: (2020)

Characteristics of Japanese Duchenne and Becker muscular dystrophy patients in a novel Japanese national registry of muscular dystrophy (Remudy)
por: Nakamura, Harumasa, et al.
Publicado: (2013)

Mitochondria mediate cell membrane repair and contribute to Duchenne muscular dystrophy
por: Vila, Maria C, et al.
Publicado: (2017)

Survival in Duchenne muscular dystrophy
por: RALL, SUSANNE, et al.
Publicado: (2012)

Theragnosis for Duchenne Muscular Dystrophy
por: Luce, Leonela, et al.
Publicado: (2021)

Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases
por: Tsoumpra, Maria K., et al.
Publicado: (2019)

Induction of Pluripotent Stem Cells from a Manifesting Carrier of Duchenne Muscular Dystrophy and Characterization of Their X-Inactivation Status
por: Miyagoe-Suzuki, Yuko, et al.
Publicado: (2017)

Early phase 2 trial of TAS‐205 in patients with Duchenne muscular dystrophy
por: Komaki, Hirofumi, et al.
Publicado: (2020)

Modelling Duchenne muscular dystrophy in MYOD1-converted urine-derived cells treated with 3-deazaneplanocin A hydrochloride
por: Takizawa, Hotake, et al.
Publicado: (2019)

Hypokalemia complicating Duchenne muscular dystrophy.
por: McDonald, B., et al.
Publicado: (1987)

The role of fibrosis in Duchenne muscular dystrophy
por: KLINGLER, WERNER, et al.
Publicado: (2012)

Delay in Diagnosis of Duchenne Muscular Dystrophy
por: Rao, Vamshi K., et al.
Publicado: (2015)

Circulating Biomarkers for Duchenne Muscular Dystrophy
por: Aartsma-Rus, Annemieke, et al.
Publicado: (2015)

Targeting angiogenesis in Duchenne muscular dystrophy
por: Podkalicka, Paulina, et al.
Publicado: (2019)

Regenerative biomarkers for Duchenne muscular dystrophy
por: Guiraud, Simon, et al.
Publicado: (2019)

Eteplirsen in the treatment of Duchenne muscular dystrophy
por: Lim, Kenji Rowel Q, et al.
Publicado: (2017)

Nutritional Challenges in Duchenne Muscular Dystrophy
por: Salera, Simona, et al.
Publicado: (2017)

Lifetime Care of Duchenne Muscular Dystrophy
por: MacKintosh, Erin W., et al.
Publicado: (2020)

The Duchenne muscular dystrophy gene and cancer
por: Jones, Leanne, et al.
Publicado: (2020)

CRISPR Therapeutics for Duchenne Muscular Dystrophy
por: Erkut, Esra, et al.
Publicado: (2022)

Gene Therapy for Duchenne Muscular Dystrophy
por: Elangkovan, Nertiyan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_kv92vjc8hkfn97o3bi70qrspbp